TIDMMHC

RNS Number : 7152O

MyHealthChecked PLC

14 June 2022

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MyHealthChecked plc

( " MyHealthChecked " or " the Company " )

Launch of at-home wellness tests

MyHealthChecked launches five new DNA tests into the consumer home-testing market

MyHealthChecked Plc (AIM: MHC), the consumer home-testing healthcare company, announces that it has launched five new at-home cheek swab DNA wellness tests, enabling individuals to make more informed choices about their health and well-being by providing a better understanding of their genetic disposition. The tests are designed to give individuals the power to be more proactive in unlocking their health potential through the management of diet and lifestyle.

Each of the tests will be priced at GBP54 and the tests currently available to purchase are:

-- Intolerances & Sensitivities - to identify genetic variants associated with intolerances, such as gluten and lactose, as well as sensitivities, including caffeine, salt and alcohol

-- Weight Management - intended for use by those wishing to identify their genetic susceptibility to becoming overweight and their responsiveness to weight loss interventions at a molecular and metabolic level, including genetic interactions

-- Heart Profile - identifying how individuals respond differently to diet. This will facilitate optimisation of heart health parameters by using personalised dietary advice

-- Vitamins & Minerals - this test indicates the predisposition towards a nutrient deficiency or toxicity, to highlight nutrients or supplements an individual should increase or deprioritise

-- Glucose Management - for individuals who aim to follow a tailored diet to adjust their intake of specific nutrients or foods to improve their glucose response

The tests will require individuals to take a simple cheek swab and return their swab in the pre-paid envelope back to MyHealthChecked's UK lab where data will be handled securely and accurately. Customers will then be able to access personalised reports, advice and guidance based on their results through the MyHealthChecked portal.

All five wellness tests will be available to purchase on the Company's website later today:

https://myhealthchecked.com/

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "I am delighted to announce the launch of our new suite of at-home wellness tests and I am proud of the efforts of the MyHealthChecked team that have allowed us to reach this milestone on time. This is a significant achievement as we move into a new phase of the business outside of the COVID-19 testing space.

"These initial tests are just the start of our consumer testing portfolio, and we look forward to updating the market on further portfolio developments throughout the course of 2022. Going forward we will continue to engage with the market on potential opportunities and re-invest the 2021 earnings from our COVID testing services to explore additional third-party technology options to further enhance the customer journey for our wellness tests. We also continue our efforts to identify and assess complementary earnings-enhancing partnerships ."

For further information contact:

 
 MyHealthChecked plc                                                www.myhealthchecked.com 
 P enny McCormick, Chief Executive                                          via Walbrook PR 
  Officer 
 
 SPARK Advisory Partners Limited                                   Tel: +44 (0)20 3368 3550 
  (NOMAD) 
 Neil Baldwin 
 
 Oberon Capital Ltd (Broker)                                       Tel: +44 (0)203 179 5344 
 Mike Seabrook                                           mikeseabrook@oberoninvestments.com 
 
 Walbrook PR Ltd (Media       Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com 
  & IR) 
 Paul McManus / Alice Woodings                             Mob: +44(0)7980 541 893 / +44(0) 
                                                                               7407 804 654 
 
 

About MyHealthChecked PLC ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

UPDUOSNRUWUNAAR

(END) Dow Jones Newswires

June 14, 2022 02:00 ET (06:00 GMT)

Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Jul 2022 a Ago 2022 Haga Click aquí para más Gráficas Concepta.
Concepta (LSE:CPT)
Gráfica de Acción Histórica
De Ago 2021 a Ago 2022 Haga Click aquí para más Gráficas Concepta.